Gene Query: OPLAH

Dataset Description Geneva Score
Glioma Stem Cell Specific Super Enhancer Drives Polyunsaturated Fatty Acid Synthesis to Support EGFR Signaling 43.61
Interactions of aCPs with Cytosine-rich Polypyrimidine Tracts Enhance Splicing of Cassette Exons 42.08
WNK1 kinase and the termination factor PCF11 connect nuclear mRNA export with transcription 30.79
Human co-transcriptional splicing kinetics and coordination revealed by direct nascent RNA sequencing 28.86
Integrated multi-omics approach reveals a role of ALDH1A1 in lipid metabolism in human colon cancer cells 27.72
Novel mutations segregating with Complete Androgen Insensitivity Syndrome and their molecular characteristics. 23.31
Identification of differential expressed genes of JQ1 or JQ1+Bortezomib in colorectal cancer cells 22.8
Knockout of miR-221 and miR-222 reveals overlapping and specific function between paralogous miRNAs 21.93
HNRNPL and its RNA Targets in Prostate Cancer 21.17
Regulartory effect of HNRNPL and LARP on RNA expression in LNCaP prostate cancer cells 21.17
hMTR4 plays a central role in creating balanced nuclear RNA pools for degradation and export 20.18
Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs with in vivo activity in hematological malignancies 19.76
Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs with in vivo activity in hematological malignancies [RNA-Seq] 19.76
Hierarchy of mono- and bi-allelic TP53 alterations in Multiple Myeloma cell fitness 15.23
Neutrophils in systemic onset Juvenile Idiopathic Arthritis display sepsis-like features which can be reverted by IL-1 blockade 14.58
Small RNA-seq of human granulosa cells reveals miRNAs in FSHR and aromatase genes 14.54
High-throughput RNA sequencing of human preovulatory cumulus and mural granulosa cells (mRNA) 14.54
EZH2 inhibitor efficacy in non-Hodgkin lymphoma does not require suppression of H3K27 mono-methylation [RNA-Seq] 14.21
EZH2 inhibitor efficacy in non-Hodgkin lymphoma does not require suppression of H3K27 mono-methylation 14.21
Quantitative analysis of bi-modal binding of BET proteins at promoters predicts I-BET sensitivity 13.95
Widespread Transcription beyond mRNA 3’ Ends Yields Abundant Regulatory RNAs 13.9
Next Generation Sequencing and m6A sequencing Facilitates Quantitative Analysis of Wild Type and genetic FTO knockdown ccRCC cells Transcriptomes 13.68
Activation of Wnt/beta-catenin in Ewing sarcoma cells antagonizes EWS/ETS function and promotes phenotypic transition to more metastatic cell states 13.01
Characterization of sperm lncRNA and its differently expression in the sperm of asthenozoospermic patients 12.93
LED, a long non-coding RNA activator of enhancer RNAs, is hypermethylated in human cancers 12.74
Proteotranscriptomic profiling of potential E6AP targets in prostate cancer cells 11.91
Gene expression profile in response to HIF-1α inhibition together with PPARα activation and the postnatal factors (T3, IGF-1 and dexamethasone) in hiPSC-CMs 10.83
Identification of long noncoding RNAs regulated by p53 10.77
RNA-sequencing of human liver tissue 10.42
RNA-seq data from human SGBS adipocytes differentiated with marine oxohexadecenoic acids 10.38
RNAseq analysis of patient-derived luminal breast cancer xenografts treated with progestins 10.38
Patient-derived luminal breast cancer xenografts with progestins 10.38
Genome-wide maps in MCF-7 cells with six2 or CYP4Z1 3'UTR or CYP4Z2P 3'UTR overexpression or not 9.87
Prostate Cancer Cell RNA-Seq (PC3E and GS689.Li) 9.8
Bromodomain-containing Protein 4 (BRD4) is Required for the Maintenance of a Mammary Epithelial Phenotype [RNA-Seq] 9.43
Bromodomain-containing Protein 4 (BRD4) is Required for the Maintenance of a Mammary Epithelial Phenotype 9.43
Spliceosomal disruption of the non-canonical BAF complex in cancer 9.43
RNA-seq Profiles in RBPJ Maintains Brain Tumor Initiating Cells through CDK9-mediated Transcriptional Elongation 9.41
RBPJ Maintains Brain Tumor Initiating Cells through CDK9-mediated Transcriptional Elongation 9.41
RNA-seq analysis of HT-29, MCF10A, and MDA-MB-436 cells 9.37
Universal alternative splicing of noncoding exons 9.27
Genome-wide chromatin analysis of Ewing sarcoma (RNA-seq) 9.18
Genome-wide chromatin analysis of Ewing sarcoma 9.18
FOXD3 is a novel tumor suppressor in lung cancer 9.01
FOXA1 Chromatin Binding is Regulated by LSD1-Mediated Demethylation 9.01
RNA-Seq with DHT induction and/or GSK treatment at 24, 48 hrs and 2 weeks 9.01
EWSR1 influences alternative splicing through direct and indirect mechanisms 9.0
RNA sequencing of lncRNAs knockdown in human pancreatic cancer cell lines 8.99
H3B-8800, a novel oral splicing modulator, induces lethality in spliceosome mutant cancers [K562] 8.84
Endogenous retroviruses are a source of oncogenic enhancers in acute myeloid leukemia [RNA-Seq] 8.41
Endogenous retroviruses are a source of oncogenic enhancers in acute myeloid leukemia 8.41
Genome-wide identification of cancer-specific alternative splicing in circRNA 8.37
RNA-seq and m6A-seq of AML cells with FTO knockdown or inhibition 8.35
Inhibition of ERG Activity in Patient Derived Prostate Cancer Xenografts using the Small Molecule Inhibitor YK-4-279 8.35
KSDM1b Role in Ewing Sarcoma 8.18
SUV420H2 knockdown in PANC-1 8.17
Therapeutic targeting of KDM1A/LSD1 in Ewing sarcoma engages the ER-stress response II 8.03
Stably-paused genes revealed through inhibition of transcription initiation by the TFIIH inhibitor Triptolide 7.93
High-Throughput Kinetic Analysis of Fractional Killing 7.64
Transcriptome analysis reveals malignant and hypoxic signature of glioblastoma 7.62
RNAseq to determine whether bidirectional transcription occurs over transposable elements following depletion of SETDB1 in THP-1 AML Cells 7.55
RNA-seq and small RNA-seq analysis of BORIS/CTCFL knockdown in K562 cell line 7.51
RNA-seq analysis of BORIS/CTCFL knockdown in K562 cell line 7.51
RNAseq to determine gene expression changes following depletion of SETDB1 in THP-1 AML Cells 7.44
Accurate annotation of human protein-coding small open reading frames 7.16
ZFR coordinates crosstalk between RNA decay and transcription in innate immunity 7.14
The conserved transcriptional landscapes in human spermatogenesis 6.97
Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of binding sites in a cell type-specific manner 6.91
Epigenetic Inactivation of Cysteine Dioxygenase Type 1 Contributes to ROS-dependent Progression of Colorectal Cancer 6.73
Differential gene expression profiles in imatinib-resistant cell lines 6.71
Effects on gene expression of ibrutinib treatment in human stem cells-derived atrial- and ventricular-like cardiomyocytes 6.64
Genome-wide probing of RNA structure reveals active unfolding of mRNA structures in vivo 6.58
Gene expression profile using RNA-seq in WC00060 or SR-0788 cells transfected with siRNA for KPC1 or control 6.46
Identification of an NKX3.1-G9a-UTY regulatory network that controls prostate differentiation (Human_RWPE1_RNA-Seq) 6.45
Identification of an NKX3.1-G9a-UTY regulatory network that controls prostate differentiation 6.45
Self-organized amniogenesis by human pluripotent stem cells in a biomimetic implantation-like niche 6.44
KMT2D regulates p63 target enhancers to coordinate epithelial homeostasis 6.39
KMT2D regulates p63 target enhancers to coordinate epithelial homeostasis [RNA-Seq] 6.39
Epigenomic landscape during organ formation in human early embryos 6.36
Transcriptome of EBV-infected gastric cancer cell lines 6.28
AKT Inhibition Promotes Non-autonomous Cancer Cell Survival 6.18
AKT Inhibition Promotes Non-autonomous Cancer Cell Survival [RNA-Seq] 6.18
RNA-seq of MCF10A cells and CAF 6.07
The pause-initiation limit restricts transcription activation in human cells 6.05
A TFIID-SAGA perturbation that targets MYB and suppresses acute myeloid leukemia (RNA-seq) 6.01
A TFIID-SAGA perturbation that targets MYB and suppresses acute myeloid leukemia 6.01
Gene expression in GBM with Cav3.2 inhibition 6.0
Modeling CADASIL vascular pathologies with patient-derived induced pluripotent stem cells 5.97
Chromatin landscape of human visceral and subcutaneous adipocytes 5.89
RNA-seq of HBV-infected Primary Human Hepatocytes treatment by Tazarotene 5.88
RNAseq Study in CC-671 Treated Cal-51 Cells 5.87
Regulation of cellular heterogeneity and rates of symmetric and asymmetric divisions in triple-negative breast cancer 5.85
Knockdown of FOXP1 promotes the development of lung adenocarcinoma 5.8
Ribosome profiling of TGFb-treated cells indicates reduced leucine availability 5.75
Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability (LNCaP RNA-seq) 5.6
Function of HNRNPC in breast cancer cells by controlling the dsRNA-induced interferon response 5.6
An improved method for circular RNA purification that efficiently removes linear RNAs containing G-quadruplexes or structured 3’ ends 5.59
POLR3G Dependent PolyA+ and smallRNA Transcriptomes in Human Pluripotent Stem Cells 5.57
Genome wide transcript and miRNAanalysis of invitro and in-vivo generated human cardiac samples 5.51
Effect of REST on cancer invasiveness in MCF-7 and MDA-MB-231 cells using RNA-sequencing (RNA-seq) analysis . 5.47
Acriflavine inhibits the epithelial-to-mesenchymal transition in vitro in liver and pancreatic cancer cells (part of study on PANC1 cells treated with CoCl2) 5.47
ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells 5.43
ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells (RNA-Seq) 5.43
RNA-seq analysis of control and NRDE2-depleted breast cancer cells 5.4
Dynamic developmental signaling logic underlying lineage bifurcations during human endoderm induction and patterning from pluripotent stem cells [Endoderm RNA-seq and ChIP-seq data sets] 5.38
Dynamic developmental signaling logic underlying lineage bifurcations during human endoderm induction and patterning from pluripotent stem cells 5.38
Anaylsis of the effect of down-regulation of the EWS-FLI1 fusion protein in Ewing Sarcoma cells by RNA-seq. 5.3
Transcriptional profile of CAOV2 ovarian cancer cells with TAZ silencing 5.29
The immediate impact of exoribonucleolysis on nuclear RNA processing, turnover and transcriptional control revealed by rapid depletion of DIS3, EXOSC10 or XRN2 from human cells 5.26
RNA Sequencing Facilitates Quantitative Analysis of Transcriptomes of H1 and H1 after SNAI1 deletion at Day2 after human early hematopoietic differentiation . 5.21
Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma 5.19
PRDM1 inhibits proliferation of human colon cancer organoids 5.18
Activation of HOTTIP lncRNA perturbs HSC function leading to AML like disease 5.17
Dynamics of Proteo-Transcriptomic Response to HIV-1 Infection 5.13
RNA-Seq analysis of human colorectal cancer with liver metastasis 5.12
Evaluating pre-clinical models for studying NASH driven HCC. 5.09
RNA seq with AML (NB4) cells upon FTO inhibition 5.06
IDH3a KO RNA-seq 5.01
A20 regulates canonical wnt-signaling through an interaction with RIPK4 5.0
GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer (RNA-Seq data set 2) 4.97
mRNA Profiling of miR-17 family inhibition using TuD lentiviral vector in HepG2 and SK-Hep1 hepatocellular carcinoma cell lines [RNA-Seq] 4.89
Lipid Nanoparticle-Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth 4.89
Targeting the androgen receptor N-terminus via the cochaperone Bag-1L [RNA-Seq KO] 4.87
RNAseq of IL-36 stimulated primary human keratinocytes 4.84
UPA-Seq: Prediction of functional lncRNAs using the sensitivities to UV-crosslinking 4.77
Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors 4.75
Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors [RNA-seq] 4.75
Exploring ILF2 regulatory genes by next-generation sequencing 4.74
Probing the Global Cellular Responses to Lipotoxicity Caused by Saturated Fatty Acids 4.72
Targeting Glioblastoma Stem Cells through Disruption of the Circadian Clock 4.68
Targeting Glioblastoma Stem Cells through Disruption of the Circadian Clock [RNA-Seq] 4.68
mRNA and RNC-mRNA deep sequencing of three hepatocellular carcinoma cell lines 4.65
Expression profiling and occupancy after knockdown or over-expression of HFN1A or HNF4G in prostate cancer cells 4.64
Loss of Function Mutations in ETS2 Repressor Factor (ERF) Reveal a Balance Between Positive and Negative ETS Factors Controlling Prostate Oncogenesis [22PC RNA-seq] 4.61
Smoking Dysregulates the Human Airway Basal Cell Transcriptome at COPD-linked Risk Locus 19q13.2 4.6
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma [RNA-seq] 4.56
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma 4.56
Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13 4.54
Grainyhead-like 2 is essential for androgen receptor expression and activity in prostate cancer 4.54
Grainyhead-like 2 is essential for androgen receptor expression and activity in prostate cancer (RNA-seq) 4.54
Mutant KRAS/BRAF Reprograms the Enhancer Landscape via GATA1 to Drive Chemoresistance 4.52
Role of OSGIN1 in Mediating Smoking-induced Autophagy in the Human Airway Epithelium [RNA-Seq] 4.52
Role of OSGIN1 in Mediating Smoking-induced Autophagy in the Human Airway Epithelium 4.52
Genome-wide Analysis of Human Constitutive Androstane Receptor (CAR) Transcriptome in Wild-type and CAR-knockout HepaRG cells 4.5
Identification of gene signature in ascitic fluid-isolated mesothelial cells from high grade serous ovarian cancer patients 4.48
RNA-seq of exosomes identifies lncRNA profiles that distinguish early-stage esophageal squamous cell carcinoma (ESCC) from non-malignant esophagitis 4.47
Developing a Novel Two-Dimensional Culture System to Enrich Human Prostate Luminal Progenitors That Can Function as a Cell of Origin for Prostate Cancer 4.43
Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability 4.4
Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability (22RV1 RNA-seq) 4.4
Identification of mesothelial-to-mesenchymal gene signature in ascitic fluid-isolated mesothelial cells through RNA-sequencing 4.39
circRNA-sequencing 4.38
Estrogen deprivation triggers and immunosuppressive phenotype in breast cancer cells 4.36
An in vitro human liver model by iPSC-derived parenchymal and non-parenchymal cells 4.32
Differential gene expression by suppression of either SOX2 or TP63 in KYSE70 human esophageal squamous carcinoma cell line. 4.29
RNA Sequencing of three pairs of gastric cancer 4.29
K562 polyA RNA-Seq 4.28
Dnmt3a and Dnmt3b associate with enhancers to regulate human epidermal stem cell homeostasis 4.24
Identification of miR-100 and miR-125b targets by AGO2 RIP-seq and RNA-seq after ectopic expression of miR-100 or miR-125b and evaluation of the TGFb expression signature in PANC-1 cells by RNA-seq 4.24
Strand-specific Dual RNA-seq of Bronchial Epithelial cells Infected with Influenza A/H3N2 Viruses Reveals Splicing of Gene Segment 6 and Novel Host-Virus Interactions 4.23
Next Generation RNA Sequencing Analysis of AMPK Wild Type, AMPKα-KO and AMPKα1-2A U2OS cell Transcriptomes 4.21
CDK12 catalytic activity is rate-limiting for RNAPII processivity on core DNA replication genes and G1/S progression 4.21
LNCaP treated with iBET 4.19
RNA-Seq study of Cell lines rendered resistant to idelalisib and ibrutinib 4.16
RNA sequencing for lncRNA, miRNA and mRNA expression analysis in human laryngeal cancer 4.16
Dynamic and stable enhancer-promoter contacts regulate terminal differentiation 4.13
Dynamic and stable enhancer-promoter contacts regulate terminal differentiation [RNA-Seq] 4.13
Valproic acid attenuates hyperglycemia induced complement and coagulation cascade gene expression 4.13
Genome-wide discovery of human splicing branchpoints [RNAse] 4.09
O-GlcNAc transferase fine-tunes MYC-dependent transcription to promote cell cycle 4.06
O-GlcNAc transferase fine-tunes MYC-dependent transcription to promote cell cycle [RNA-seq] 4.06
TT-Seq captures the human transient transcriptome 4.05
The effect of REST and its alternatively spliced transcript, REST-003, on breast cancer invasiveness 4.04
Gene expression profiling associated with knockdown of RNF20 in human normal and malignant lung epithelial cell lines 3.99
Investigate A2M treatment on human prostate cancer xenograft in mice 3.99
Investigate A2M treatment on human prostate cancer and mouse liver 3.99
Transcriptome profiling of HepG2 cells upon treatment of the menin-MLL inhibitor MI-503 or DMSO 3.91
Targeting the androgen receptor N-terminus via the cochaperone Bag-1L [RNA-seq C-terminal mutant] 3.91
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer (RNA-Seq) 3.88
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer 3.88
Analyses of a panel of transcripts and construction of RNA networks in hepatocellular carcinoma 3.82
MDM2 and MDM4 are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors 3.76
ZNF131 suppresses centrosome fragmentation in Glioblastoma stem-like cells through regulation of HAUS5 3.76
Identification of the RB loss-induced transcriptome and E2F1 cistrome in prostate cancer 3.76
Identification of the RB loss-induced transcriptome in prostate cancer [RNA] 3.76
RNA-seq data for non-targeting siRNA and CDK11 siRNA transfection in SHhES8 cells 3.7
RNA-seq analysis of uveal melanoma cells treated with FR900359 3.67
A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities. 3.62
RNA-sequencing of mRNAs from control and CAP-D3 deficient Salmonella infected HT-29 cells 3.62
Androgen Receptor-regulated genes in prostate cancer cells 3.58
RNA-seq profiling identifies Androgen Receptor-regulated genes in prostate cancer cells 3.58
ZEB1 insufficiency causes corneal endothelial cell state transition and altered cellular processing 3.58
Forkhead domain mutations in FOXA1 drive prostate cancer cell progression 3.58
RNA-seq in LNCaP cell line overexpressing WT or mutant FOXA1 3.58
Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade 3.56
BAF controls genome accessibility 3.56
The expression profiles of GBC liver metastasis 3.48
LINC00520 is Induced by Src, STAT3, and PI3K and Plays a Functional Role in Breast Cancer 3.46
RNA-seq analysis of A2780 and OVCAR3 human ovarian cancer cell lines after overexpression of collagen type XI alpha 1 (COL11A1) 3.44
NRDE2 negatively regulates nuclear exosome functions 3.41
Gene expression analysis of immortalized human liver progenitor-like cells in culture 3.4
RNA-Seq with and without RNase treatment in PCa cell lines 3.39
Expanding the Nucleoside Recoding Toolkit: Revealing RNA Population Dynamics with 6-thioguanisine 3.36
RNA-seq of PC3 prostate cancer cell line xenografts in mice administered the ghrelin receptor antagonist [D-Lys3]-GHRP-6 or PBS for two weeks 3.35
RNA sequencing of human mammary epithelial cells 3.35
The RNA helicase DDX39B regulates IL7R alternative splicing reducing the risk of Multiple Sclerosis 3.33
Uridylation by TUT4 and TUT7 marks mRNA for degradation 3.32
RNAseq of Breast cancer PDX samples 3.31
Next-generation RNA sequencing to determine changes in gene expression during breast cancer progression 3.3
Paxillin regulates genomic networks in prostate cancer [PC3] 3.29
Acetyl-CoA carboxylase inhibition regulates microtubule dynamics and intracellular transport in cystic fibrosis epithelial cells 3.27
LncRNA-dependent mechanisms of androgen receptor-regulated gene activation programs 3.26
The anti-leukemic effect of R-2HG depends on its acting as an m6A mRNA modifier-RNA Seq-PBS / R-2HG treatment 3.23
Gene expression changes in THP1 cells at day 2 and 4 following shRNA knock-down of RUVBL2 3.21
Next Generation Sequencing of Transcriptomes of Cutaneous Melanocytes and Metastatic Melanoma Cell Lines 3.21
Next Generation Sequencing of Transcriptomes of Cutaneous Melanocytes and Metastatic Melanoma Cell Lines (mRNA-Seq) 3.21
Innate-like activation of mucosal-associated invariant T cells in mycobacterial infection 3.19
Gene Expression Profiling of SPOP Knocked Down Cell 3.18
MeRIP-seq for heat shock in B-cell lymphoma cells 3.17
Determination of a comprehensive alternative splicing regulatory network and the combinatorial regulation by key factors during Epithelial-to-Mesenchymal Transition [ESRP KD] 3.15
Quantitative Analysis of PPARD Transcriptomes in Colon Cancer Cells by Next Generation Sequencing (NGS) 3.1
RNA-Seq profiling of iPSC-derived ventricular and atrial cardiomyocytes 3.09
N6-methyladenine DNA Modification in Glioblastoma 3.09
N6-methyladenine DNA Modification in Glioblastoma [RNA-seq] 3.09
TMED9-gated CNIH4 and TGFa signaling promotes pro-metastatic states in human primary colon cancer cells 3.09
SPOP mutation confers intrinsic BET inhibitor resistance in prostate cancer (BRD4_JQ1_RNA-seq) 3.07
RNA seq data of Hep3B-control, Hep3B-sertraline, Hep3B-XL413, Hep3B-XL413-sertraline, Huh7-control, Huh7-sertraline, Huh7-XL413, Huh7-XL413-sertraline cells 3.04
Distinct roles of cohesin-SA1 and cohesin-SA2 in 3D chromosome organization  3.01
RNA-sequencing analysis for gene expression profiles affected by CASC9 knockdown 3.0
Transcriptome splicing analysis in K562 cells expressing rare and private spliceosomal mutations 2.99
RNA-seq of H1299 cells in which either PRKCI or SOX2 was silenced by validated lentiviral shRNA constructs 2.95
The Human Testis Cell Atlas via Single-cell RNA-seq 2.95
Transcriptome analysis of human reninomas as an approach to understanding juxtaglomerular cell biology 2.93
Diffuse Large B Cell Lymphoma cell line with Acquired Resistance to PI3Kδ Inhibitor Idelalisib 2.92
Discovery of naturally occurring ESR1 mutations during acquisition of resistance to endocrine therapy in widely used estrogen receptor positive breast cancer cell lines [RNA-Seq] 2.92
Discovery of naturally occurring ESR1 mutations during acquisition of resistance to endocrine therapy in widely used estrogen receptor positive breast cancer cell lines 2.92
RNA Seq analysis of NKX2-5 Null and Het human embryonic stem cells in cardiomyogenesis 2.88
Altering cancer transcriptomes using epigenomic inhibitors [RNA-Seq] 2.86
Altering cancer transcriptomes using epigenomic inhibitors 2.86
Paxillin regulates genomic networks in prostate cancer [LNCaP] 2.82
Expression charcaterization of an internal protocol developed to differentiate RPE cells 2.82
Recovery and analysis of nascent RNA 2.8
The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains 2.8
Mutation independent activation of the Notch pathway is associated with Lapatinib resistance in Her2+ breast cancer cell lines 2.79
Repurposing of promoters and enhancers during mammalian evolution 2.79
Expression changes in melanoma cell lines under BRAFi treatment timepoints [RNA-Seq.CellLine.batch4] 2.78
Functional Screening in Human Cardiac Organoids Reveals a Metabolic Mechanism for Cardiomyocyte Maturation 2.77
Identification of long noncoding RNAs in T-ALL cell lines 2.76
hMTR4 plays a central role in creating balanced nuclear RNA pools for degradation and export II 2.76
MYCi361 regulates MYC target genes 2.76
RNA-seq of human iPS derived macrophages with or without KLF1- transcription factor Activation 2.75
Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance 2.75
Total RNA sequencing of APC mutant and wt colonic organoids 2.72
H1609088 Human RNA-Sequencing 2.71
Energy Metabolism during Anchorage-Independence 2.7
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary (I) 2.69
Multivalent binding of PWWP2A to H2A.Z-marked transcriptional active chromatin regulates mitosis and organ development [RNA-seq] 2.69
Multivalent binding of PWWP2A to H2A.Z-marked transcriptional active chromatin regulates mitosis and organ development 2.69
Next Generation Sequencing of human SMA and healthy control Motor Neurons 2.67
The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth 2.67
RNA-sequencing WT vs SOCS3 knockout Glioblastoma stem-cells 2.61
BRG1 recruitment by transcription factors MITF and SOX10 defines a specific configuration of regulatory elements in the melanocyte lineage 2.6
BRG1 recruitment by transcription factors MITF and SOX10 defines a specific configuration of regulatory elements in the melanocyte lineage (RNA-seq) 2.6
Human Induced Pluripotent Stem Cells Recapitulate Breast Cancer Patients’ Predilection to Doxorubicin-Induced Cardiotoxicity 2.59
Selective roles of vertebrate PCF11 in premature and full-length transcript termination (chromatin-bound RNA-seq) 2.57
Transcriptome of EMT induced MCF10A cells by TGFb treatment or SNAIL S6A expression. 2.55
CDK12 catalytic activity is rate-limiting for RNAPII processivity on core DNA replication genes and G1/S progression (nuclear RNA) 2.54
Developmental origins define epigenomic differences between subcutaneous and visceral adipocytes [RNA-Seq] 2.51
Inactivation of CFTR by CRISPR/Cas9 alters transcriptional regulation of inflammatory pathways and other networks 2.49
Transcriptomic Reprogramming of Prostate Cancer Cells Driven by Stroma-Derived SPINK1 2.45
Effect of CRISPR-Cas9 mediated knock-out of integrin alpha2 on the transcriptome of DU145 prostate cancer cell grown as a spheroid culture 2.44
Expansion, in vivo-ex vivo cycling and genetic manipulation of primary human hepatocytes 2.44
Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation 2.44
Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation (RNA-Seq) 2.44
Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures [RNA-seq] 2.43
Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures 2.43
TWIST1-induced microRNA-424 drives an intermediate epithelial-to-mesenchymal transition that opposes metastasis 2.42
The phosphatidylinositol 3-kinase pathway as a potential therapeutic target in bladder cancer 2.42
Searching for target genes of miR-508/509/506/514 in HCT116 cells 2.39
A Werner syndrome stem cell model unveils heterochromatin alterations as a driver of human aging 2.38
Expression profiling by high throughput sequencing of tumors derived from human prostate epithelial cells transformed with the oncogenes N-Myc and myrAKT1. 2.37
Genome-wide analysis of YAP and TFCP2 down-regulated genes in liver cancer cells 2.36
Genome-wide analysis of YAP and TFCP2 occupancy and regulated expression in liver cancer cells 2.36
KAP1 regulates ERVs in differentiated human cells and contributes to innate immune control 2.35
Azithromycin induces epidermal differentiation and multivesicular bodies in airway epithelia 2.35
Iron response of HepG2 cells 2.35
Transcriptomic but not genomic variability confers phenotype of breast cancer stem cells 2.32
A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor 2.31
PTEN interacts with the transcription machinery on chromatin and regulates RNA polymerase II-mediated transcription.[RNA-seq and ChIP-seq] 2.3
PTEN interacts with the transcription machinery on chromatin and regulates RNA polymerase II-mediated transcription 2.3
Effect of venetoclax, tedizolid, and combination treatment on gene expression in a venetoclax-resistant AML cell line 2.3
Arnica montana stimulates extracellular matrix gene expression in human macrophages differentiated to wound-healing phenotype. Tested on 5 concentrations. 2.26
The Human Testis Cell Atlas via Single-cell RNA-seq (Healthy men scRNA-seq data set) 2.25
RNA-seq of YB5 and MCF7 treated with different doses of decitabine 2.23
Acquired resistance to MEK-CDK4/6 inhibitor combinations in cutaneous melanoma 2.23
Human Embryoid Body Transcriptomes Reveal Maturation Differences Influenced by Size and Formation in Custom Microarrays 2.2
Combinatorial Regulation Mediated by Biochemically Distinct Forms of SWI/SNF [RNA-Seq] 2.18
Genome-Wide Transcriptional Regulation Mediated By Biochemically Distinct Forms of SWI/SNF 2.18
U2AF1 mutations alter splice site recognition in hematological malignancies 2.17
Histone variant H2A.Bbd is associated with active transcription and mRNA processing in human cells [RNA-Seq] 2.17
Histone variant H2A.Bbd is associated with active transcription and mRNA processing in human cells 2.17
Transcriptome analysis of human cumulus cells reveals hypoxia as the main determinant of follicular senescence. 2.15
Gene expression analysis of human hepatocellular cancers 2.14
Hyper-activation of HUSH complex function by Charcot-Marie-Tooth disease mutation in MORC2 2.13
LIN28A modulates splicing and gene expression programs in breast cancer cells 2.13
LIN28A modulates splicing and gene expression programs in breast cancer cells [RNA-Seq] 2.13
A novel non-canonical signaling pathway mediates TGF-β1-induced glucocorticoid insensitivity in epithelial cells 2.12
Gene expression profiling of neural crest progenitor cultures derived from human embryonic stem cells carrying nonsense mutations in the Polycomb gene ASXL1 [HOM] 2.12
MRTF activates TEAD-YAP target gene expression 2.11
RNA profiling Analysis of the Serum Exosomes Derived from Active and Latent M.tuberculosis infectious Patients 2.11
RNA-seq transcriptonal profiling in human K562 cells with or without dCas9 and sgRNAs 2.09
In situ CAPTURE of chromatin interactions by biotinylated dCas9 2.09
A genomic study of the contribution of DNA methylation to regulatory evolution in primates 2.07
Altered mRNA splicing by mutant p53 activates oncogenic RAS in pancreatic cancer 2.07
Genome-wide discovery of human splicing branchpoints 2.07
Defective transcription elongation in a subset of cancers confers immunotherapy resistance (BGI12 RNA-Seq) 2.06
Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer 2.02
Adaptation of the Kinome Promotes Resistance to BET Bromodomain Inhibitors in Ovarian Cancer 1.98
RNA-seq of RKO cells with cTAZ KO or putback 1.98
Impaired DNA damage metabolism promotes autoimmunity in TREX1 deficiency  1.96
RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates Fasudil as an anti-leukemic drug. 1.96
ARID1A and ARID1B loss in HCT116 and TOV21G cells 1.95
MEIS2 is a novel oncogenic partner in AML1-ETO positive AML 1.9
MEIS2 is a novel oncogenic partner in AML1-ETO positive AML [RNA-Seq human] 1.9
Identification and mitigation of pervasive off-target activity in CRISPR-Cas9 screens for essential non-coding elements 1.9
Integrating the Epigenome to Identify Novel Drivers of Hepatocellular Carcinoma 1.88
A histone H3.3 Lysine 36 Trimethylation Reader Connects Chromatin to Regulated Pre-mRNA Processing 1.86
Quantitative profiling of the UGT transcriptome in human drug metabolizing tissues [Total RNA] 1.8
Human ES Cell-derived Hepatoblasts are an Optimal Lineage Stage for HCV Infection 1.77
Effect of MDK expressing Melanoma cells conditioned media in Human LEC 1.76
Targetting super enhancer associated oncogenes in esophageal squamous cell carcinoma [RNA-seq] 1.75
Targetting super enhancer associated oncogenes in esophageal squamous cell carcinoma 1.75
Human Hepatocytes with Drug Metabolic Function Induced from Fibroblasts by Lineage Reprogramming 1.72
Differentially Expressed Genes for Atrial Fibrillation Identified using RNA Sequencing from Paired Human Left and Right Atrial Appendages. 1.7
Transcriptomes change differerntly in differernt cancer cells upon EPZ-6438 treatment 1.69
Transcriptional Profiling of Werner Syndrome (WS) iPSC-derived MSC and the isogenic gene-edited controls 1.69
CRISPR-mediated deletion of prostate cancer risk-associated CTCF loop anchors identifies repressive chromatin loops 1.69
Molecular Signature of CAID Syndrome: Noncanonical Roles of SGO1 in Regulation of TGF-β Signaling and Epigenomics. 1.68
Molecular Signature of CAID Syndrome: Noncanonical Roles of SGO1 in Regulation of TGF-β Signaling and Epigenomics. [RNA-seq] 1.68
RNA-Seq and expression data from human adipose tissue 1.64
Tissue-specific RNA-seq in human evoked inflammation identifies novel blood and adipose lincRNA signatures of cardio-metabolic diseases 1.64
Transcriptional responses of melanoma cells to BRAF inhibition 1.63
Profiling of circular RNAs in gastric cancer tissues and adjacent normal tissues 1.62
mRNA sequencing analysis of cultured human primary airway epithelial cells upon exposure to PMN exosomes 1.6
Molecular analysis of renal cell carcinoma with unclassfied histology 1.57
Molecular analysis of renal cell carcinoma with unclassfied histology [gene expression] 1.57
A High-Throughput Screen Identifies DYRK inhibitor ID-8 that Stimulates Human Kidney Tubular Proliferation 1.56
shRNA-mediated knockdown of ETV4 and MED25 in the prostate cell line PC3 reveals set of genes potentially coregulated by MED25 and ETV4 1.55
Genome-wide occupancy of FLAG-MED25 and ETV4 and expression profiling of shRNA-mediated knockdown of ETV4 and MED25 in the prostate cell line PC3 1.55
Low carbohydrate diet study for non-alcoholic fatty liver disease patients 1.55
Connexin 32-mediated cell-cell communication is essential for hepatic differentiation from human embryonic stem cells 1.55
Genome-wide functional assessment of enhancer activities in the human genome 1.54
Genomic Reorganization of Lamin-Associated Domains in Cardiac Myocytes is Associated with Differential Gene Expression and DNA Methylation in Human Dilated Cardiomyopathy [RNA-Seq] 1.54
Genomic Reorganization of Lamin-Associated Domains in Cardiac Myocytes is Associated with Differential Gene Expression and DNA Methylation in Human Dilated Cardiomyopathy 1.54
Comparative transcriptome analysis reveals that ECM-Receptor Interaction contributes to the venous metastases of hepatocellular carcinoma 1.5
SNHG15 is a bifunctional MYC-regulated noncoding locus encoding a lncRNA that promotes cell proliferation, invasion and drug resistance in colorectal cancer by interacting with AIF 1.49
Charaterization of genetic alterations and gene expression signatures found in BCR-ABL inhibitor-resistant KCL-22 subpopulations and single clones 1.48
Browning of human adipocytes requires KLF11 and reprogramming of PPARγ super-enhancers 1.48
Evolution of an lncRNA leads to a primate specific modulation of alternative splicing 1.45
Effect of SF3B1 suppression in cancer cells with different SF3B1 copy-number levels 1.43
Specific inhibition of DPY30 activity by peptides suppresses blood cancer cell growth 1.42
Disease-associated mutation in SRSF2 misregulates splicing by altering RNA binding affinities 1.42
Targeting MTHFD2 in Acute Myeloid Leukemia 1.4
Defective transcription elongation in a subset of cancers confers immunotherapy resistance 1.38
Identification of Tissue-Specific Protein-Coding and Noncoding Transcripts across 14 Human Tissues Using RNA-seq 1.37
Acetylation of spliceosome protein PHF5A modulates stress responses and colorectal carcinogenesis through alternative splicing mediated upregulation of KDM3A 1.37
Transcriptomic analysis of human iPS cells derived from fragile X syndrome patients during neural differentiation 1.36
Transcriptomic analysis of the role of the integrin a6b4 in detached cells 1.31
ERK signaling regulates opposing functions of JUN family transcription factors in prostate cancer cell migration 1.3
Splicing and gene expression changes in human mammary epithelial MCF-10A cells expressing SR or SR-like proteins 1.29
Circular RNA profiling reveals the different distribution/characteristic and possible transport mechanism among the subcellular fractions 1.28
Abnormal RNA splicing and genomic instability after induction of DNMT3A mutations by CRISPR/Cas9 gene editing [RNA-Seq] 1.28
Abnormal RNA splicing and genomic instability after induction of DNMT3A mutations by CRISPR/Cas9 gene editing 1.28
The landscape of alternative splicing in aggressive prostate cancers 1.23
ARS2 is a general suppressor of pervasive transcription [RNAseq] 1.21
Time-dependent regulation of cellular programming of monocytes by NCOR2 [RNASeq_KD] 1.15
BioProject PRJNA381064: Convergent origination of a Drosophila-like dosage compensation mechanism in a reptile lineage (Gene expression profiling in several tetrapod species, bulk tissue RNA-seq) 1.15
ENCODE Cold Spring Harbor Labs Long RNA-seq 1.14
RNA sequencing of human pancreatic cancer cell lines 1.13
RNA sequencing of heart samples of myotonic dystrophic (DM1) patients 1.11
Differential susceptibility of human pleural and peritoneal mesothelial cells to asbestos exposure 1.11
Myeloid-derived suppressor cells facilitie invasion and metastasis of papillary thyroid cancer cells by repressing miR-486-3p 1.04
Insulin receptor associates with promoters genome-wide and regulates gene expression [RNA-seq 2] 1.02
Transcriptome sequencing identify a recurrent CRYL1-IFT88 chimeric transcript in hepatocellular carcinoma 1.02
Discovery and verification of liver cancer marker genes and variable scission based on second-generation sequencing data analysis 0.99
Short-term effect of Boost versus Radical doses of Intraoperative electron Radiotherapy in breast cancer tumor bed using high-throughput approaches 0.98
Transcriptome-wide modulation of splicing by the exon junction complex 0.97
Loss of CHD1 facilitates oncogenic hijacking of AR during cancer progression 0.96
Loss of CHD1 facilitates oncogenic hijacking of AR during cancer progression [RNA-seq] 0.96
RB tumor suppressor promotes cancer immunity through downregulating PD-L1 expression 0.96
Genomic expression analysis of K562 cells expressing shRNA targeting lncRNA-IIRX and control cells 0.95
Deep sequencing of transcript levels of human embryonic stem cell derived mesothelium (epithelial and mesenchymal forms) and mesothelium from neonatal mouse E15.5 of the heart, lung, liver and gut and ChIP-seq data of the mesenchymal form of mesothelium 0.95
Zone dependent distinctive gene expression profile of the normal human liver tissue 0.92
Oncogenic changes and EMT in normal human bile duct epithelial cells are caused by parasite-derived materials and N-nitrosodimethylamine 0.92
Gene expression, methylome and splicing of THP-1 monocytic cells and THP-1-derived macrophage 0.89
RNA-seq study reveals unique transcriptome expression in systemic lupus erythematosus patients with distinct autoantibody profile 0.87
Whole blood RNAseq from Generalised Pustular Psoriasis patients and healthy individuals 0.87
KLF4 as a rheostat of osteolysis and osteogenesis in prostate tumors in the bone 0.84
ELF1 expression in prostate cells reduces oncogenic ETS functions and promotes senescence and sensitivity to chemotherapy through distinct gene expression programs [RNA-seq] 0.83
ELF1 expression in prostate cells reduces oncogenic ETS functions and promotes senescence and sensitivity to chemotherapy through distinct gene expression programs 0.83
Dissecting the single-cell transcriptome network underlying gastric premalignant lesions and early gastric cancer [10x genomics] 0.8
AMPK signaling for naïve pluripotency [Hs] 0.79
AMPK signaling for naïve pluripotency 0.79
Canonical and non-canonical regulatory roles of androgen receptor variant 7 in prostate cancer 0.77
Analysis of gene expression, motif and pattern of m6A modified region and m6A enrichment level in Ocular melanoma and Melanocyte cell lines. Gene expressin analysis of METTL3 knock down in PIG1, ALKBH5 knock down and HINT2 over expression in OCM1. 0.76
Survival of pancreatic cancer cells lacking KRAS function 0.74
RNA-Sequencing shows novel transcriptomic signatures in failing and non-failing human heart 0.74
Comprehensive comparative analysis of RNA sequencing methods for degraded or low input samples 0.73
Gene expression profile in endometrial organoids cultured in normal follicular phase vs PCOS-like hormone profile 0.73
High-throughput RNA sequencing on circular RNA profiles of human triple-negative breast cancer and adjacent normal tissues 0.72
Disruption of Na+/H+ exchanger regulatory factor 2 scaffold suppresses colon cancer proliferation 0.72
Preclinical model of obesity and ER-positive breast cancer 0.72
Insulin receptor associates with promoters genome-wide and regulates gene expression [RNA-seq] 0.69
Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition 0.68
Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition [RNA-Seq] 0.68
Exercise-induced transcriptome changes in skeletal muscle adapted to aerobic training 0.66
The transcriptome of Kawasaki Disease arteritis 0.65
CDK4/6 inhibitor resistance in prostate cancer 0.65
Transcriptome landscape of HeLa response upon triamcinolone acetonide 0.64
Gene expression and chromatin organization changes in lamin A/C haploinsufficient human induced pluripotent stem cell-derived cardiomyocytes 0.62
Gene expression and chromatin organization changes in lamin A/C haploinsufficient human induced pluripotent stem cell-derived cardiomyocytes [RNA-seq] 0.62
RNA Missplicing in Fuchs Endothelial Corneal Dystrophy 0.61
TALENs-mediated gene disruption of FLT3 in leukemia cells: Using genome-editing approach for exploring the molecular basis of gene abnormality 0.59
Oncogenic Antisense LncRNA P14AS Regulates Expression of ANRIL through AUF1 Binding 0.59
The circadian transcriptional landscape in primary human mammary epithelial cells 0.58
Novel kinase fusion oncogenes in post-Chernobyl radiation-induced pediatric thyroid cancers 0.58
RNA-seq in neutrophils from Juvenile Idiopathic Arthritis 0.55
TrapSeq: An RNA Sequencing-based pipeline for the identification of genetrap insertions in mammalian cells 0.54
Campylobacter concisus pathotypes induce distinct global responses in intestinal epithelial cells [UNSWCD] 0.53
Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. 0.53
Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. 0.53
Functional genomic analysis of the haploinsufficient tumor suppressor, CUX1 0.52
Analysis of human, chimpanzee, macaque and mouse tissue transcriptomes using Next Generation Sequencing 0.52
Zika virus infection reprograms global transcription of host cells to allow sustained infection 0.51
Effect of circPTPRM on the biological behaviors of hepatocellular carcinoma cells in vitro and its clinical significance. 0.49
Modeling genome-wide transcriptional cis-regulation in n LNCaP-abl cell line after siRNA knock down of a series of gene factors [RNA-seq] 0.49
CSL RNA-Seq on HKC and SCC cell lines 0.46
CSL 0.46
Effects of Spaceflight on Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Structure and Function 0.46
Identification of epigenetic interactions between miRNA and DNA methylation associated with polycystic ovarian syndrome 0.45
Transcriptome Profiling Reveals the key genes and pathways involved in polycystic ovary syndrome [RNA-seq] 0.45
Functional Haploid Human Oocytes Generated from Polar Body Genomes (RNA-Seq) 0.45
Functional Haploid Human Oocytes Generated from Polar Body Genomes 0.45
HNRNPM-regulated splicing dependencies in prostate cancer [RNA-Seq] 0.44
HNRNPM-regulated splicing dependencies in prostate cancer 0.44
Gene expression profile of multiple myeloma cell lines treated with CB-5083 0.43
RNA-sequencing of the human milk fat layer during colostrum, transitional, and mature stages of lactation 0.43
RNA-Seq analysis of human neutrophils isolated by different protocols (Polymorphprep and negative selection) and incubated with and without in vitro cytokine stimulation 0.41
Effects of transcription factor CEBPA knockdown on vitamin D target gene regulation in THP-1 cells 0.4
The pioneer factor CEBPA modulates vitamin D signaling 0.4
T-cell ALL in response to TAL1-KD, UTX-KD, and GSKJ4 treatment 0.4
Gene expression in TAL1-driven T-cell ALL in response to TAL1-KD, UTX-KD, and GSKJ4 treatment 0.4
Epigenomic conservation of transposable element silencing 0.39
Epigenomic conservation of transposable element silencing [RNA-seq] 0.39
SPOP mutation confers intrinsic BET inhibitor resistance in prostate cancer 0.38
The DNA methylation landscape of human melanoma [RNA-Seq] 0.37
The DNA methylation landscape of human melanoma 0.37
A robust qualitative transcriptional signature for the early diagnosis of gastric cancer 0.37
Trascriptome of thyroid cancer-induced macrophages 0.36
A Low-cost Multiplex Biomarker Assay Stratifies Colorectal Cancer Patient Samples into Clinically-relevant Subtypes: Singapore Cohort RNA-seq 0.36
A Low-cost Multiplex Biomarker Assay Stratifies Colorectal Cancer Patient Samples into Clinically-relevant Subtypes 0.36
RNA-seq analysis of human KMT2A rearranged MV4;11 AML cell line treated with DOT1L and/or EZH2 inhibitor 0.34
Epigenome Editing by CRISPR/Cas9 Repressors for Silencing of Distal Regulatory Elements 0.33
Wnt addiction of genetically defined cancers reversed by PORCN inhibition 0.32
Recurrent alterations of TNFAIP3 (A20) in T-cell large granular lymphocytic leukemia 0.32
Histone H3.1K27 methylation promotes NHEJ by antagonizing FANCD2 on Chromatin 0.32
MYC interacts with the G9a histone methyltransferase to drive transcriptional repression and tumorigenesis 0.32
Illumina HiSeq Sequencing on Breast cancer PDX samples 0.31
RNA-Seq expression profiling of hepatocellular carcinoma and adjacent non-tumor liver tissues 0.31
Neutrophils RNAseq from Generalised Pustular Psoriasis patients and healthy individuals 0.31
Screening in Human Cardiac Organoids Identifies a Requirement for the Mevalonate Pathway in Cardiomyocyte Proliferation 0.31
Gene expression profiling of patient's DCIS-IDC tandem lesions by RNA sequencing analysis 0.29
Immunophenotyping and Transcriptomic Outcomes in PDX-Derived TNBC Tissue 0.27
CpG dinucleotides introduced into gag can inhibit HIV-1 gene expression by modulating pre-mRNA splicing 0.23
An electrical pulse stimulation protocol to study acute epigenetic response to muscle cell contraction uncovers acute hydroxymethylation of the exercise-responsive gene Nr4a3 0.23
An electrical pulse stimulation protocol to study acute epigenetic response to muscle cell contraction uncovers acute hydroxymethylation of the exercise-responsive gene Nr4a3 [RNA-Seq] 0.23
Genome-wide maps of transcriptomic and epigenomic state in melanoma cell lines 0.23
RNA-Sequencing of HepG2 cells treated with TGFBeta 0.22
Identification of miRNA-mRNA regulatory network for Human Atrial Aging 0.22
Identification of miRNA-mRNA regulatory network for Human Atrial Aging [mRNA] 0.22
RNA expression profiles comparing primary and omental ovarian carcinoma samples 0.21
Identification of the O-GlcNAc-regulated alternative splicing events by performing RNA sequencing on HeLa cells with altered O-GlcNAc level. 0.2
RNA-sequencing of pediatric idiopathic dilated cardiomyopathy patients and healthy controls 0.18
Transcriptomics-based drug repurposing approach identifies novel drugs against sorafenib-resistant hepatocellular carcinoma 0.17
Reconstituting development of pancreatic intraepithelial neoplasia from primary human pancreas duct cells 0.17
ERK potentiates transactivation and oncogenic function of ERG by phosphorylation induced dissociation of PRC2 complex 0.17
SREBP1 drives Keratin 80-dependent cytoskeletal changes and invasive behavior in endocrine resistant ERα breast cancer 0.16
Patient-derived organoids (PDOs) model treatment response of metastatic gastrointestinal cancers. 0.15
The SS18-SSX fusion oncoprotein hijacks BAF complex targeting and function to drive synovial sarcoma [RNA-Seq Tumor] 0.1
Transcriptome profiling of de-differentiated chondrocytes over-expressing miR-138 or miR-181ab1 during osteogenic induction 0.05
Expression data for HT29 cells treated with 5-aza-deoxy-cytidine 0.05
Expression data for HT29 cells treated with 5-aza-deoxy-cytidine [RNA-Seq] 0.05
Activating Transcription Factor 4 modulated TGFb-induced aggresiveness in triple negative breast cancer vis SMAD2/3/4 and mTORC2 signaling 0.05
Lung adenocarcinoma metastasis is suppressed by the alveolar lineage transcription factors GATA6 and HOPX. 0.05
Landscapes of gene translation in hepatocellular carcinoma tumors revealed by ribosome profiling 0.04
Gene expression profile of melanoma cell lines after overexpression or knockdown of KPC1 0.03
Enhancer activation during EGF response 0.03
Gene Expression Profile of human hepatocellular carcinoma by RNA sequencing 0.03
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma 0.02
Paclitaxel plus Cirmtuzumab Achieves Greater Clearance of Patient-derived Xenografts By Targeting ROR1+ Breast Cancer Stem Cells 0.02
RNA-Seq identifies condition-specific biological signatures of ischemia-reperfusion injury in the human kidney 0.0


Contact Us

For scientific and technical queries contact Butte Lab @UCSF


Cite GENEVA Tool

Manuscript in Preparation